期刊
ANNALS OF SURGICAL ONCOLOGY
卷 28, 期 13, 页码 8884-8891出版社
SPRINGER
DOI: 10.1245/s10434-021-10307-4
关键词
-
资金
- William and Susan Johnson Fund for Endocrine Surgery Research
Despite the challenges in managing thyroid nodules, molecular testing platforms have been developed to improve cancer risk assessment for patients with cytologically indeterminate nodules, and have been incorporated into guidelines as an important diagnostic adjunct. Numerous studies have demonstrated the accuracy and utility of molecular testing in the contemporary management of thyroid nodules.
Despite advances in imaging and biopsy techniques, the management of thyroid nodules often remains a diagnostic and clinical challenge. In particular, patients with cytologically indeterminate nodules often undergo diagnostic thyroidectomy although only a minority of patients are found to have thyroid malignancy on final pathology. More recently, several molecular testing platforms have been developed to improve the stratification of cancer risk for patients with cytologically indeterminate thyroid nodules. Based on numerous studies demonstrating its accuracy, molecular testing has been incorporated as an important diagnostic adjunct in the management of indeterminate thyroid nodules in the National Comprehensive Cancer Network Guidelines as well as in the American Thyroid Association (ATA) and American Association of Endocrine Surgeons (AAES) guidelines. This overview describes the currently available molecular testing platforms and highlights the published data to date on the clinical validity and utility of molecular testing in the contemporary management of thyroid nodules.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据